3B Blackbio DX Ltd
3B Blackbio DX Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
Not discussed on this call: margin, order book.
The short version
The company targets a revenue growth of 15% to 20% for FY27 and onward. 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
From 3B Blackbio DX Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a revenue growth of 15% to 20% for FY27 and onward.
- Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28.
- The overall consolidated topline for FY27 is expected to be INR175-180 crores.
- The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%.
- Competition from China affects a small product segment but is not expected to impact the core high-margin AMR panel business.
- Market growth is anticipated at 8%-10% over the next 2-3 years, with the company maintaining approximately 15% market share.
- Growth is supported by new product launches such as sample-to-answer systems expected around Q3-Q4, and ongoing US FDA approvals enhancing global presence.
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
- Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores.
- Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments.
- There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities.
- M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates.
- The company aims to keep a cash reserve of INR 50 crores specifically for M&A deals.
- Slight uncertainties exist on timing; M&A closures are expected during the year but exact Q1/Q2 timing is not guaranteed.
- Treasury investments are diversified into equity mutual funds (5-7%), fixed deposits (30-35%), treasury bonds (30-35%), and AAA-rated corporate bonds, maintaining liquidity for acquisitions.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Coris contract initially was Euro 6 million for four years starting 2024.
- Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million).
- Around Euro 2.4 million remains to be executed through FY28.
- The Coris HAT order is expected to remain broadly similar in the current year.
- Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays.
- For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive.
- Market demand projected to grow at 8% to 10%, with 3B BlackBio maintaining around 15% market share.
- No major market glut expected from China or competitors in India or export markets due to regulatory barriers.
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
- Health X Platform Ltd (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
- Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
- Vimta Labs Ltd (Q4 FY26)
. Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q4 FY26 results?
The company targets a revenue growth of 15% to 20% for FY27 and onward. 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a below-average growth signal. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.